MYRIAD GENETICS INC's ticker is MYGN and the CUSIP is 62855J104. A total of 192 filers reported holding MYRIAD GENETICS INC in Q3 2022. The put-call ratio across all filers is 0.37 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2023 | $2 | -100.0% | 68 | -82.9% | 0.00% | – |
| Q2 2022 | $7,000 | -30.0% | 398 | 0.0% | 0.00% | – |
| Q1 2022 | $10,000 | -9.1% | 398 | 0.0% | 0.00% | – |
| Q4 2021 | $11,000 | -15.4% | 398 | 0.0% | 0.00% | – |
| Q3 2021 | $13,000 | +8.3% | 398 | 0.0% | 0.00% | – |
| Q2 2021 | $12,000 | 0.0% | 398 | 0.0% | 0.00% | – |
| Q1 2021 | $12,000 | +500.0% | 398 | +696.0% | 0.00% | – |
| Q3 2018 | $2,000 | -100.0% | 50 | -100.0% | 0.00% | -100.0% |
| Q2 2016 | $6,182,000 | +24.5% | 202,035 | +52.3% | 0.03% | +21.4% |
| Q1 2016 | $4,965,000 | +339.8% | 132,645 | +299.3% | 0.03% | +366.7% |
| Q2 2015 | $1,129,000 | -3.9% | 33,217 | 0.0% | 0.01% | 0.0% |
| Q1 2015 | $1,175,000 | +28.3% | 33,217 | +23.5% | 0.01% | +20.0% |
| Q4 2014 | $916,000 | +740.4% | 26,900 | +740.6% | 0.01% | +400.0% |
| Q1 2014 | $109,000 | -98.3% | 3,200 | -98.9% | 0.00% | -97.8% |
| Q4 2013 | $6,294,000 | +31.2% | 300,000 | +68.0% | 0.04% | +4.7% |
| Q2 2013 | $4,798,000 | – | 178,574 | – | 0.04% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Camber Capital Management LP | 5,000,000 | $90,850,000 | 3.94% |
| Altium Capital Management LP | 221,000 | $4,016,000 | 1.61% |
| DISCIPLINED GROWTH INVESTORS INC /MN | 1,900,787 | $34,537,000 | 0.93% |
| Zebra Capital Management LLC | 15,352 | $279,000 | 0.82% |
| PFM Health Sciences, LP | 1,177,250 | $21,391,000 | 0.82% |
| EARNEST PARTNERS LLC | 6,462,138 | $117,417,000 | 0.78% |
| Glenview Capital Management | 1,696,791 | $30,831,000 | 0.77% |
| AIMZ Investment Advisors, LLC | 42,085 | $765,000 | 0.37% |
| Phocas Financial Corp. | 127,949 | $2,325,000 | 0.35% |
| Redhawk Wealth Advisors, Inc. | 34,680 | $630,000 | 0.29% |